Last reviewed · How we verify
insulin delivery
Insulin delivery refers to a system or technology platform for administering insulin to patients, rather than a specific molecular drug.
Insulin delivery refers to a system or technology platform for administering insulin to patients, rather than a specific molecular drug. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | insulin delivery |
|---|---|
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This appears to be a delivery technology or device platform developed by Medical University of Graz for improved insulin administration in diabetes management. Without more specific information about the particular formulation, device type, or novel mechanism, the exact mechanistic details cannot be precisely characterized. Insulin delivery systems typically aim to improve glycemic control, patient compliance, or reduce injection burden.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus requiring insulin therapy
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipohypertrophy
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) (PHASE4)
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
- The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment (NA)
- Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery
- Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery (NA)
- Closed-loop in Adults With Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin delivery CI brief — competitive landscape report
- insulin delivery updates RSS · CI watch RSS
- Medical University of Graz portfolio CI